Skip to main content
Journal cover image

Heart failure drug treatment.

Publication ,  Journal Article
Rossignol, P; Hernandez, AF; Solomon, SD; Zannad, F
Published in: Lancet
March 9, 2019

Heart failure is the most common cardiovascular reason for hospital admission for people older than 60 years of age. Few areas in medicine have progressed as remarkably as heart failure treatment over the past three decades. However, progress has been consistent only for chronic heart failure with reduced ejection fraction. In acutely decompensated heart failure and heart failure with preserved ejection fraction, none of the treatments tested to date have been definitively proven to improve survival. Delaying or preventing heart failure has become increasingly important in patients who are prone to heart failure. The prevention of worsening chronic heart failure and hospitalisations for acute decompensation is also of great importance. The objective of this Series paper is to provide a concise and practical summary of the available drug treatments for heart failure. We support the implementation of the international guidelines. We offer views on the basis of our personal experience in research areas that have insufficient evidence. The best possible evidence-based drug treatment (including inhibitors of the renin-angiotensin-aldosterone system and β blockers) is useful only when optimally implemented. However, implementation might be challenging. We believe that disease management programmes can be helpful in providing a multidisciplinary, holistic approach to the delivery of optimal medical care.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Lancet

DOI

EISSN

1474-547X

Publication Date

March 9, 2019

Volume

393

Issue

10175

Start / End Page

1034 / 1044

Location

England

Related Subject Headings

  • Stroke Volume
  • Sodium-Glucose Transporter 2 Inhibitors
  • Randomized Controlled Trials as Topic
  • Humans
  • Heart Failure
  • General & Internal Medicine
  • Diuretics
  • Disease Progression
  • Angiotensin II Type 1 Receptor Blockers
  • Acute Disease
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rossignol, P., Hernandez, A. F., Solomon, S. D., & Zannad, F. (2019). Heart failure drug treatment. Lancet, 393(10175), 1034–1044. https://doi.org/10.1016/S0140-6736(18)31808-7
Rossignol, Patrick, Adrian F. Hernandez, Scott D. Solomon, and Faiez Zannad. “Heart failure drug treatment.Lancet 393, no. 10175 (March 9, 2019): 1034–44. https://doi.org/10.1016/S0140-6736(18)31808-7.
Rossignol P, Hernandez AF, Solomon SD, Zannad F. Heart failure drug treatment. Lancet. 2019 Mar 9;393(10175):1034–44.
Rossignol, Patrick, et al. “Heart failure drug treatment.Lancet, vol. 393, no. 10175, Mar. 2019, pp. 1034–44. Pubmed, doi:10.1016/S0140-6736(18)31808-7.
Rossignol P, Hernandez AF, Solomon SD, Zannad F. Heart failure drug treatment. Lancet. 2019 Mar 9;393(10175):1034–1044.
Journal cover image

Published In

Lancet

DOI

EISSN

1474-547X

Publication Date

March 9, 2019

Volume

393

Issue

10175

Start / End Page

1034 / 1044

Location

England

Related Subject Headings

  • Stroke Volume
  • Sodium-Glucose Transporter 2 Inhibitors
  • Randomized Controlled Trials as Topic
  • Humans
  • Heart Failure
  • General & Internal Medicine
  • Diuretics
  • Disease Progression
  • Angiotensin II Type 1 Receptor Blockers
  • Acute Disease